
Sickle Cell Disease
Evidence was presented at EHA2025 that the agent improves RBC health and blood flow in patients.
Two cases of patients with SCD and history of delayed hemolytic transfusion reaction were presented at EHA2025.
The analysis was an assessment of 15-year follow-up data from the CLIMB study and was presented at EHA2025.
Vivien Sheehan, MD, explained how a novel assay can guide personalized therapeutic approaches for sickle cell disease.
Rilzabrutinib significantly decreased spleen weight and reduced inflammation in mice with homozygous sickle cell genotype.
MIRCA is a device designed to assess the flexibility of red blood cells of patients with sickle cell disease.
Compared with placebo, crizanlizumab has superior safety and comparable efficacy in patients with sickle cell disease.
The study led by Paul George, MD, PhD, also highlights the importance of patient regimen adherence to secure these benefits.
The findings coincide with patient reports of experiencing increased vaso-occlusive episodes during menses.
The Foundation for Sickle Cell Disease Research will evaluate VAS-101 in a phase 1 clinical study.
Advertisement
Expert Interviews on Hematology
;